International Journal of Clinical Oncology

, Volume 17, Issue 6, pp 604–609 | Cite as

Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

  • Yosuke Horita
  • Yasuhide Yamada
  • Ken Kato
  • Yoshinori Hirashima
  • Kouhei Akiyoshi
  • Kengo Nagashima
  • Takako Nakajima
  • Tetsuya Hamaguchi
  • Yasuhiro Shimada
Original Article

Abstract

Objective

FOLFIRI is a standard chemotherapy regimen for the treatment of metastatic colorectal cancer. Although some studies have shown its efficacy in combination with bevacizumab as first-line chemotherapy, there are no data to support FOLFIRI plus bevacizumab as second-line chemotherapy in patients with this form of cancer. The aim of this study was to evaluate the efficacy and safety of FOLFIRI and bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.

Methods

Eligible patients were ≥20 years old, previously treated (except with irinotecan [CPT-11] and bevacizumab), with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and adequate organ function. Twenty-five eligible patients received FOLFIRI with bevacizumab at a dose of 10 mg/kg given intravenously on day 1. All therapy was administered every 2 weeks until disease progression. The primary endpoint was the response rate.

Results

Twenty-five patients were enrolled between February 2008 and March 2009. The median age was 62 (range 38–73) years, the male/female distribution was 20/5, 16 patients had performance status 0 and 9 had performance status 1, and the proportion of patients who were oxaliplatin pretreated/untreated was 16/9. The overall response rate was 32% (90% confidence interval [CI]: 17.0–50.4%), with 8 patients showing partial responses, 15 with stable disease, and 2 with disease progression. Median progression-free survival was 11.6 months (95% CI: 6.9–16.4). Median overall survival was 21.4 months (95% CI: 12.0–30.8). The grade 3/4 adverse events with treatment were neutropenia (64%), leukopenia (16%), diarrhea (8%), anorexia (8%), and febrile neutropenia (8%). The bevacizumab-related grade 3/4 adverse event was hypertension, which was observed in 12% of patients.

Conclusions

The FOLFIRI plus bevacizumab regimen is an active, well-tolerated second-line chemotherapy treatment for patients with metastatic colorectal cancer.

Keywords

FOLFIRI Bevacizumab Second-line Colorectal cancer 

References

  1. 1.
    Jemal A, Tiwari RC, Murray T et al (2004) American Cancer Society, Cancer Statistics 2004. CA Cancer J Clin 54:8–29PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543PubMedCrossRefGoogle Scholar
  3. 3.
    Cancer Statistics in Japan Editorial Board. Cancer Statistics in Japan 2008. Foundation for Promotion of Cancer Research 2008 (in Japanese)Google Scholar
  4. 4.
    Tsukuma H, Ajiki W, Ioka A et al (2006) Survival of cancer patients diagnosed between 1993 and 1996: a collaborative study of population-based cancer registries in Japan. Jpn J Clin Oncol 36:602–607PubMedCrossRefGoogle Scholar
  5. 5.
    Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041–1047PubMedCrossRefGoogle Scholar
  6. 6.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRefGoogle Scholar
  7. 7.
    Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRefGoogle Scholar
  8. 8.
    Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26(4):689–690PubMedCrossRefGoogle Scholar
  9. 9.
    NCCN Clinical Practice Guidelines. http://www.nccn.org/index.asp
  10. 10.
    Therasse P, Arbuck S, Eisenhauer E et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  11. 11.
    National Cancer Institute—Common Toxicity Criteria (NCI-CTC Version 3.0, March 31, 2003). http://www.jcog.jp
  12. 12.
    Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544PubMedCrossRefGoogle Scholar
  13. 13.
    Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237PubMedCrossRefGoogle Scholar
  14. 14.
    Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11:853–860PubMedCrossRefGoogle Scholar
  15. 15.
    Padera TP, Stoll BR, Tooredman JB et al (2004) Pathology: cancer cells compress intratumour vessels. Nature 427(6976):695PubMedCrossRefGoogle Scholar
  16. 16.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2011

Authors and Affiliations

  • Yosuke Horita
    • 1
    • 2
  • Yasuhide Yamada
    • 1
  • Ken Kato
    • 1
  • Yoshinori Hirashima
    • 3
  • Kouhei Akiyoshi
    • 1
  • Kengo Nagashima
    • 4
  • Takako Nakajima
    • 1
  • Tetsuya Hamaguchi
    • 1
  • Yasuhiro Shimada
    • 1
  1. 1.Gastrointestinal Oncology DivisionNational Cancer Center HospitalTokyoJapan
  2. 2.Department of ChemotherapyToyama Prefectural Central HospitalToyamaJapan
  3. 3.Department of Medical Oncology, Faculty of MedicineOita UniversityOitaJapan
  4. 4.Laboratory of Biostatistics, Faculty of Pharmaceutical SciencesJosai UniversitySaitamaJapan

Personalised recommendations